medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2007, Number 2

<< Back Next >>

Rev Med UV 2007; 7 (2)

Prolactin and prostate cancer

Rodríguez S, Herrera D, Becerra P, Silva M, Locia J, Martínez M, González Z, Hernández AME

Language: Spanish
References: 23
Page: 26-31
PDF size: 391.18 Kb.


ABSTRACT

Prolactin is a protein hormone produced and synthesized by lactotrophs in the adenohipophysis. This hormone has several functions including those related to the reproduction. In this sense, it has been shown that prolactin had receptors in different sexual glands, being the prostate one of them. In this gland, prolactin induces synthesis and release of the prostatic semen, but also this hormone regulates the proliferation-apoptosis mechanism. The latter function is so important because following proliferation increase there is a high probability to develop prostatic pathologies like cancer. Up to date, there is a lot of information trying to explain the mechanisms triggered by prolactin to promote this pathology. However, the information still is not so clear. The knowledge today points up to a relationship between prolactin and testosterone in regulating the normal physiological conditions of the prostate; but in pathological conditions, the evidence favors a regulation of androgen receptors induced by prolactin. This could explain in general the effect of prolactin on the development of pathology in the prostate. This relationship between prolactin and steroid hormones in relation with the prostate function is central in this review.


REFERENCES

  1. Ouhtit A, Morel G, Kelly PA. Visualization of gene expression of short and long forms of prolactin receptor in rat reproductive tissues. Biol. Reprod. 1993; 49: 528-536.

  2. Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate. 1994; 24:162-166.

  3. Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL. Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinol. 1996; 137: 3078-3088.

  4. Hair WM, Gubbay O, Jabbour HN, Lincoln GA. Prolactin receptor expression in human testis and accessory tissues: localization and function. Mol Hum Reprod. 2002; 8: 606-611.

  5. Thomson CH, Thompson DL Jr, Kincaid LA, Nadal MR. Prolactin involvement with the increase in seminal volume after sexual stimulation in stallions. J Anim Sci. 1996; 74: 2468-2472.

  6. Janssen T et al. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer. 1996; 77:144-149.

  7. Van Coppenolle F, et al. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation. Biochem J. 2004; 377:569-578.

  8. Crepin A, et al. Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression. Biochem J. 2007; 401:49-55.

  9. de Launoit Y, et al. Influences of dihydrotestosterone, testosterone, estradiol, progesterone, or prolactin on the cell kinetics of human hyperplastic prostatic tissue in organ culture. Prostate. 1988. 13:143-153.

  10. Leav I, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol. 1999; 154:863-870.

  11. Reiter E, et al. Effects of pituitary hormones on the prostate. Prostate. 1999; 38:159-165.

  12. Harvey PW, Everet DJ, Springall CJ. Hyperprolactinemia as an effect in regulatory and clinical toxicology: role in breast and prostate cancer. Human Experimental Toxicol. 2006; 25:395-404.

  13. Lissoni P. et al. A phase II study of tamoxifen in hormone-resistance metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res. 2005a; 25: 3597-3599.

  14. Lissoni P. et al. Possible involvement of prolactin in endocrine-resistant metastasic prostate cancer. Int. J. Biol. Markers. 2005b; 20: 123-125.

  15. Horti J. et al. A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep. 1998; 5:893-896

  16. So AI, Hurtado-Coll A, Gleave ME. Androgens and prostate cancer. World Urol. 2003; 21: 325-337.

  17. Doherty PC, Baum MJ, Todd RB. Effects of chronic hyperprolactinemia on sexual arousal and erectile function in male rats. Neuroendocrinology. 1986; 42:368-375.

  18. Doherty PC, et al. Extra-hypothalamic dopamine is not involved in the effects of hyperprolactinemia on male copulatory behaviour. Physiol Behav. 1989; 45: 1101-1105.

  19. Kruger TH, et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol. 2003; 179: 357-365.

  20. Hernandez ME, et al. Prostate response to prolactin in sexually active male rats. Reprod Biol Endocrinol. 2006; 4: 28.

  21. Hernandez ME, et al. A study of the prostate, androgens and sexual activity of male rats. Reprod Biol Endocrinol. 2007; 5:11

  22. Panidis D, et al. Evaluation of semen parameters in man with hyperprolactinemia induced by metoclopramide. Arch Androl. 1997; 39: 237-242.

  23. De Rosa M, et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf). 2006; 64:307-313.




2020     |     www.medigraphic.com